ResMed Inc. — Form 10-K summary
Reporting period: Fiscal year ended June 30, 2020, filed August 12, 2020. Although the request metadata says “2019 Q4,” this filing reports fiscal 2020; it also includes fourth-quarter results. Amounts below are U.S. dollars.
Business context
ResMed develops and sells connected medical devices and software for sleep apnea, respiratory care and out-of-hospital healthcare. Its two segments are Sleep and Respiratory Care and software as a service (SaaS). Products are sold in approximately 140 countries. The company employed about 7,770 people at year-end.
Key financial results
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $2,957.0 million | $2,606.6 million | +13% reported; +15% constant currency |
| Gross profit / margin | $1,717.8 million / 58.1% | $1,494.1 million / 57.3% | Profit +15%; margin +0.8 percentage points |
| Operating income | $809.7 million | $579.3 million | +40% |
| Net income | $621.7 million | $404.6 million | +54% |
| Diluted EPS | $4.27 | $2.80 | +53% |
| Operating cash flow | $802.3 million | $459.1 million | +$343.2 million |
| Cash and cash equivalents, year-end | $463.2 million | $147.1 million | +$316.0 million |
| Gross debt, year-end | $1,176.1 million | $1,270.9 million | −$94.7 million |
| Working capital, year-end | $920.7 million | $589.4 million | +$331.3 million |
Approximate net margin was 21.0%, compared with 15.5% in FY2019. Cash and $1.1 billion of undrawn revolving capacity provided reported combined cash and available liquidity of approximately $1.5 billion. The company paid $225.1 million in dividends and repurchased no shares during FY2020.
Revenue and material year-over-year changes
- Sleep and Respiratory Care revenue was $2,602.4 million, up 12% reported and 13% in constant currency. Devices generated $1,507.8 million, up 11%; masks and other products generated $1,094.6 million, up 13%.
- SaaS revenue was $354.6 million, up 29%, reflecting MatrixCare revenue for a fuller comparable period and continued growth in software offerings. Segment operating profit was $82.2 million, versus $74.9 million.
- Sleep and Respiratory Care segment operating profit was $934.7 million, versus $766.1 million. Segment results exclude corporate and other unallocated items.
- Revenue growth reflected higher device and mask unit sales, including pandemic-driven ventilator demand. Gross margin improved on favorable product mix, partly offset by higher COVID-related manufacturing and logistics costs and acquisition-related intangible amortization.
- Net income also benefited from a lower effective tax rate: 15.2% versus 22.0%. Management cited geographic earnings mix and tax benefits from vesting or settlement of employee share awards.
Quarterly context, outlook and notable items
- FY2020 fourth-quarter revenue was $770.3 million, versus $705.0 million in FY2019 Q4; net income was $177.8 million, versus $68.8 million. Diluted EPS was $1.22 versus $0.48. The filing attributes pandemic-era demand shifts and the prior-year litigation expense to the differing results.
- Management said ventilator demand increased during FY2020 but expected lower ventilator demand in FY2021, with further outbreaks and demand levels uncertain. It also expected COVID-19 to temporarily reduce new-patient demand for sleep devices; resupply demand was expected to be less affected.
- COVID-19 disrupted sleep-apnea diagnostic and prescription pathways, constrained manufacturing through labor and component availability, and could weigh on SaaS customer acquisition and expansions. Management reported that the pandemic had not negatively affected liquidity as of the filing.
- FY2019 included $41.2 million of litigation settlement expense. The December 2019 settlement resolved U.S. government allegations for a $39.5 million payment plus associated fees and costs; ResMed also entered a five-year Corporate Integrity Agreement requiring additional sales and pricing controls and monitoring. FY2020 includes a $0.6 million settlement-expense credit.
- The Australian Taxation Office assessed $151.7 million of additional tax, $38.4 million of interest and asserted $75.9 million in penalties relating to 2009–2013. ResMed disputes the assessments, has paid $75.9 million (recorded as a receivable), and says the remaining amounts are payable only if it loses its challenge. The ATO is also auditing 2014–2018.
- Debt covenants were reported in compliance. Variable-rate borrowings were charged at 1.2% at year-end; senior notes include $250 million due in 2026 at 3.24% and $250 million due in 2029 at 3.45%.
Investor facts to verify
- Confirm the period distinction: this is a fiscal 2020 annual report, not a standalone 2019 Q4 filing; compare the reported Q4 figures with the company’s quarterly release.
- Track FY2021 ventilator demand, inventory levels and the recovery of sleep-apnea diagnosis and new-patient treatment pathways.
- Assess whether SaaS growth and profitability persist after the acquisition-driven contribution from MatrixCare and other acquired businesses.
- Review debt repayment, undrawn facility availability, variable-rate exposure and covenant headroom.
- Monitor the ATO dispute, including potential tax, interest and penalty exposure, and compliance costs or operating effects under the Corporate Integrity Agreement.
- Note that the auditor issued unqualified opinions on the financial statements and internal control; goodwill impairment and the Australian tax assessments were identified as critical audit matters.